Últimas

Canadian PM Shuffles Cabinet as Major Health Studies Warn on Eczema, Meat Consumption; Lilly's Oral Weight-Loss Drug Shows Strong Results

16.9.25

OTTAWA – Canadian Prime Minister Mark Carney announced changes to his cabinet today in a significant political shake-up. The day's news was also dominated by major public health revelations from Europe, with one study linking atopic eczema to a higher risk of suicidal thoughts and another showing widespread concern among doctors over meat consumption. In the pharmaceutical world, Eli Lilly published promising Phase 3 results for its investigational oral weight-loss drug.

Political Shake-up in Ottawa

Prime Minister Mark Carney announced adjustments to his Ministry, a move aimed at positioning his government for the upcoming parliamentary session. The changes include a new role for Chrystia Freeland, who currently serves as Minister of Transport and Internal Trade.

In addition to the cabinet shuffle, the Prime Minister met with canola industry leaders from across Canada's Prairie provinces to discuss key issues facing the agricultural sector.

Public Health in the Spotlight with European Studies

Two significant European studies raised public health alarms. A new international study presented at the EADV Congress 2025 in Paris revealed a deeply concerning link between atopic eczema and mental health, finding that adults with the chronic skin condition have a significantly higher risk of suicidal thoughts.

Separately, a survey commissioned by Madre Brava found that 91% of European doctors and dietitians believe that current meat consumption levels in Europe are unhealthy. The concern is so high that 95% of the health professionals surveyed called for health warnings to be placed on red and processed meat products.

Major Developments in Pharmaceuticals and Clean Energy

In a major development for the treatment of obesity, Eli Lilly announced the complete results from its Phase 3 ATTAIN-1 study for orforglipron, its investigational once-daily oral GLP-1 pill. Published in The New England Journal of Medicine, the results showed the drug led to meaningful weight loss, averaging 27.3 lbs (12.4%) at the highest dose by week 72, alongside cardiometabolic improvements.

In the clean energy sector, LanzaJet applauded the Australian government's landmark $1.1 billion (AUD) investment to advance the country's sustainable fuels industry. Meanwhile, in the critical battery supply chain, Aquatech announced it has acquired Koch Technology Solutions' direct lithium extraction (DLE) business, a key technology for producing lithium, a vital component for electric vehicle batteries.

Flurry of Legal Actions Target Public Companies

A notable trend of the day was the flurry of announcements from investor rights law firms, including Hagens Berman and Rosen Law Firm. A multitude of securities class action lawsuits and investigation deadlines were announced, targeting a wide range of publicly traded companies.

The allegations varied, from misleading investors about financial health and revenue inflation to inadequate clinical trials. Companies facing new lawsuits or approaching lead plaintiff deadlines include KinderCare (KLC), SelectQuote (SLQT), C3.ai (AI), Lockheed Martin (LMT), and Snap Inc. (SNAP), among many others.

Business and Tech Briefs

  • G-P, a global employment platform, was named an industry leader in NelsonHall's 2025 Global Employer of Record (EOR) market analysis for the fifth consecutive time, highlighting its AI-powered technology.

  • Banorte, led by Carlos Hank Gonzalez, was recognized by Global Finance as the Best Digital Bank in Mexico and Latin America, with its mobile application winning top honors.

  • Kinley, an industrial services firm, is celebrating 130 years in business, marking six generations of family ownership and leadership.

  • In a significant U.S. health policy development, the HHS and CDC announced the first-ever appointment of a pharmacist, Hillary F. Blackburn, as a voting member of the Advisory Committee on Immunization Practices (ACIP).


Nenhum comentário

Assinar: Postar comentários ( Atom )